Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI)
  • Together, Clearmind and Aragen will advance MEAI to clinical testing as a treatment for Alcohol Use Disorder and binge drinking
  • Preclinical studies were extremely favorable, demonstrating a high safety profile and promising efficacy
  • Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics
  • Shares in Clearmind Medicine Inc. (CMND) are up 8.22 per cent, trading at $0.79 per share

Clearmind Medicine (CMND) will work with Aragen Life Sciences to produce its innovative molecule, 5-Methoxy-2-aminoindane (MEAI).

Aragen is a global leader in providing discovery, development and manufacturing solutions for life sciences firms.

Together, Clearmind and Aragen will advance MEAI to clinical testing as a treatment for Alcohol Use Disorder and binge drinking.

MEAI is a unique synthetic, psychedelic molecule that simulates the euphoric alcohol experience while simultaneously reducing the desire to consume alcohol.

Preclinical studies were extremely favourable, demonstrating a high safety profile and promising efficacy.

Under the agreement, Aragen will optimize the production and synthesis of the molecule, as well as manufacture and supply MEAI to Clearmind.

Adi Zuloff-Shani, CEO of Clearmind, commented,

“Developing a pharmaceutical product is quite arduous; working with a manufacturer in Aragen’s caliber allows us to focus all our resources on furthering the research.”

Clearmind is now preparing for a pre-investigational new drug (IND) meeting with the United States Food and Drug Administration, which the company will follow up with an IND application and clinical trial in the second half of 2022.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics.

Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

Shares in Clearmind Medicine Inc. (CMND) are up 8.22 per cent, trading at $0.79 per share as of 11:05 am ET.

More From The Market Herald
BioMark Diagnostics - Founder and CEO, Rashid Bux

" BioMark (CSE:BUX) to collaborate with AstraZeneca and Pfizer Canada to improve early detection of lung cancer

BioMark Diagnostics (BUX) will participate in a research project that aims to enhance the efficiency of lung cancer screening programs.

" Algernon Pharmaceuticals (CSE:AGN) welcomes new CFO

Algernon Pharmaceuticals (AGN) has appointed Mr. James Kinley as the Chief Financial Officer (CFO), effective December 1, 2021.

" Beyond Medical Technologies (CSE:DOCT) ramps up mask manufacturing in response to new South African variant

Beyond Medical Technologies (DOCT) subsidiary Micron Technologies has been manufacturing medical masks in British Columbia since August 2020.

" Sun Life Financial (TSX:SLF) partners with CloudMD (TSXV:DOC)

Sun Life (SLF) has partnered with CloudMD (DOC) to add its Mental Health Coach solution to group benefits plans.